The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Open accessPublished version of a preprint
Abstract
UNLABELLED: Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular characterization. Cell-free DNA (cfDNA) sequencing may enable a precision oncology approach in this setting. We attempted to prospectively analyze 54 genes in tumor and cfDNA for 26 patients. Tumor sequencing failed in 9 patients (35%). In the remaining 17, 90.3% (95% confidence interval, 73.1%-97.5%) of mutations detected in tumor biopsies were also detected in cfDNA. The diagnostic accuracy of cfDNA sequencing was 97.7%, with 92.3% average sensitivity and 100% specificity across five informative genes. Changes in cfDNA correlated well with tumor marker dynamics in serial sampling (r = 0.93). We demonstrate that cfDNA sequencing is feasible, accurate, and sensitive in identifying tumor-derived mutations without prior knowledge of tumor genotype or the abundance of circulating tumor DNA. cfDNA sequencing should be considered in pancreatobiliary cancer trials where tissue sampling is unsafe, infeasible, or otherwise unsuccessful. SIGNIFICANCE: Precision medicine efforts in biliary and pancreatic cancers have been frustrated by difficulties in obtaining adequate tumor tissue for next-generation sequencing. cfDNA sequencing reliably and accurately detects tumor-derived mutations, paving the way for precision oncology approaches in these deadly diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to other reports for tissue NGS (46), quantity of tDNA was not sufficient for 24 of 52 (46.2%) patients.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“As a result, most genomic research in PDA has centered around tumor-derived cell lines or xenografts in lieu of direct tumor sequencing(7), and expert bodies currently make no recommendations regarding molecular profiling for clinical decision-making in PDA(8), despite potentially sensitive subsets identified by seque…”
BackgroundRyan, D. P., Hong, T. S., & Bardeesy, N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1404198 · Cited by 2,348
Cited by
Sorted by citations
Application of Cell-free DNA Analysis to Cancer Treatment
Corcoran, R. B., & Chabner, B. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1706174 · Cited by 980
Lanman, R. B., Mortimer, S. A., Zill, O. A., Sebisanovic, D., Lopez, R., Blau, S., Collisson, E. A., Divers, S. G., Hoon, D. S. B., Kopetz, E. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140712 · Cited by 695
“In addition, this external validation study showed that 90% of mutations detected in tumor biopsies were also detected in cfDNA and that diagnostic test performance was consistent or better than reported here with cfDNA sensitivity of 92%, specificity 100% and diagnostic accuracy of 98% across five informative genes […”
ResultThe emerging role of cell-free DNA as a molecular marker for cancer management
Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566
Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 488
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367
Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325
“NGS (46), quantity of tDNA was not sufficient for 24 of 52 (46.”
BackgroundMolecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
The influence of subclonal resistance mutations on targeted cancer therapy
Schmitt, M. W., Loeb, L. A., & Salk, J. J. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.175 · Cited by 234
Genomic and Epigenomic Alterations in Cancer
Chakravarthi, B. V. S. K., Nepal, S., & Varambally, S. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.02.023 · Cited by 232
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Ilyas, S. I., Affò, S., Goyal, L., Lamarca, Á., Sapisochín, G., Yang, J. D., & Gores, G. J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00770-1 · Cited by 224
A Comparison of Cell-Free DNA Isolation Kits
Sorber, L., Zwaenepoel, K., Deschoolmeester, V., Roeyen, G., Lardon, F., Rolfo, C. D., & Pauwels, P. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.09.009 · Cited by 212
Lucas, F. A. S., Allenson, K., Bernard, V., Castillo, J., Kim, D. U., Ellis, K. E. S., Ehli, E. A., Davies, G. E., Petersen, J. L., Li, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv604 · Cited by 209
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions
Cheng, M. L., Pectasides, E., Hanna, G. J., Parsons, H. A., Choudhury, A. D., & Oxnard, G. R. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21650 · Cited by 201
Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer
Takai, E., Totoki, Y., Nakamura, H. K., Morizane, C., Nara, S., Hama, N., Suzuki, M., Furukawa, E., Kato, M., Hayashi, H., et al. (2015) · Scientific Reports · doi:10.1038/srep18425 · Cited by 196
Krüger, S., Heinemann, V., Ross, C. M. D., Diehl, F., Nagel, D., Ormanns, S., Liebmann, S., Prinz-Bravin, I., Westphalen, C. B., Haas, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy417 · Cited by 165
Tjensvoll, K., Lapin, M., Buhl, T., Oltedal, S., Berry, K. S.-O., Gilje, B., Søreide, J. A., Javle, M. M., Nordgård, O., & Smaaland, R. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.012 · Cited by 157
He, C., Liu, C., Jiang, J., Luo, G., Yu, L., Jin, K., Guo, M., Zhang, Z., Xu, J., Liu, L., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30650 · Cited by 145
Lamarca, Á., Kapacee, Z. A., Breeze, M., Bell, C., Belcher, D., Staiger, H., Taylor, C., McNamara, M. G., Hubner, R. A., & Valle, J. W. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092854 · Cited by 145
Zhou, J., Wang, C., Lin, G., Xiao, Y., Jia, W., Xiao, G., Liu, Q., Wu, B., Wu, A., Qiu, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2299 · Cited by 141
Krook, M. A., Lenyo, A. M., Wilberding, M., Barker, H. D., Dantuono, M., Bailey, K. M., Chen, H., Reeser, J. W., Wing, M. R., Miya, J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0631 · Cited by 144
Chae, Y. K., Davis, A. A., Jain, S., Santa-Maria, C. A., Flaum, L., Beaubier, N. T., Platanias, L. C., Gradishar, W. J., Giles, F. J., & Cristofanilli, M. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0061 · Cited by 140
Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates
Kis, O., Kaedbey, R., Chow, S., Danesh, A., Dowar, M., Li, T., Li, Z., Liu, J., Mansour, M., Masih‐Khan, E., et al. (2017) · Nature Communications · doi:10.1038/ncomms15086 · Cited by 137
Lapin, M., Oltedal, S., Tjensvoll, K., Buhl, T., Smaaland, R., Garresori, H., Javle, M. M., Glenjen, N. I., Abelseth, B. K., Gilje, B., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1677-2 · Cited by 135
Using circulating cell-free DNA to monitor personalized cancer therapy
Oellerich, M., Schütz, E., Beck, J., Kanzow, P., Plowman, P. N., Weiss, G. J., & Walson, P. D. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1299683 · Cited by 133
Sefrioui, D., Blanchard, F., Touré, E., Basile, P., Beaussire, L., Dolfus, C., Perdrix, A., Paresy, M., Antonietti, M., Iwanicki–Caron, I., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.250 · Cited by 124
Ko, A. H., Bekaii‐Saab, T., Ziffle, J. V., Mirzoeva, O. K., Joseph, N. M., Talasaz, A. H., Kühn, P., Tempero, M. A., Collisson, E. A., Kelley, R. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0979 · Cited by 121
Ettrich, T. J., Schwerdel, D., Dolnik, A., Beuter, F., Blätte, T. J., Schmidt, S. A., Stanescu-Siegmund, N., Steinacker, J., Marienfeld, R. B., Kleger, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-49860-0 · Cited by 120
Huang, A., Zhao, X., Yang, X., Li, F., Zhou, X., Wu, K., Zhang, X., Sun, Q., Cao, Y., Zhu, H., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.005 · Cited by 118
Blood biomarkers for differential diagnosis and early detection of pancreatic cancer
Al-Shaheri, F. N., Alhamdani, M. S. S., Bauer, A. S., Giese, N. A., Büchler, M. W., Hackert, T., & Hoheisel, J. D. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102193 · Cited by 119
Chae, Y. K., Davis, A. A., Agte, S., Pan, A. P., Simon, N. I., Iams, W. T., Cruz, M. R. D. S., Tamragouri, K., Rhee, K., Mohindra, N. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0433 · Cited by 118
Labgaa, I., Villacorta-Martín, C., D’Avola, D., Craig, A. J., von Felden, J., Martins-Filho, S. N., Sia, D., Stueck, A., Ward, S. C., Fiel, M. I., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0206-3 · Cited by 117
Liquid Biopsy, ctDNA Diagnosis through NGS
Chen, L., Liu, X., Zheng, B., Ke, R., & Tzeng, C. (2021) · Life · doi:10.3390/life11090890 · Cited by 117
Chae, Y. K., Davis, A. A., Carneiro, B. A., Chandra, S., Mohindra, N., Kalyan, A., Kaplan, J., Matsangou, M., Pai, S., Costa, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11692 · Cited by 110
Arechederra, M., Rullán, M., Amat, I., Oyón, D., Zabalza, L., Elizalde, M., Latasa, M. U., Mercado, M., Ruiz-Clavijo, D., Saldaña, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325178 · Cited by 111
DNA in extracellular vesicles: from evolution to its current application in health and disease
Ghanam, J., Chetty, V. K., Barthel, L., Reinhardt, D., Hoyer, P. F., & Thakur, B. K. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00771-0 · Cited by 123
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Rizzo, A., Ricci, A. D., Tavolari, S., & Brandi, G. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20203 · Cited by 107
Wei, T., Zhang, Q., Li, X., Su, W., Li, G., Ma, T., Gao, S., Lou, J., Que, R., Zheng, L., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1298 · Cited by 102
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
Patel, H., Okamura, R., Fanta, P. T., Patel, C., Lanman, R. B., Raymond, V. M., Kato, S., & Kurzrock, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0824-4 · Cited by 99
Okajima, W., Komatsu, S., Ichikawa, D., Miyamae, M., Ohashi, T., Imamura, T., Kiuchi, J., Nishibeppu, K., Arita, T., Konishi, H., et al. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i31.5650 · Cited by 98
Kim, M. K., Woo, S. M., Park, B., Yoon, K., Kim, Y., Joo, J., Lee, W. J., Han, S., Park, S., & Kong, S. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.283721 · Cited by 96
Platelets, circulating tumor cells, and the circulome
Marie, P. K., Lam, M. S., Menter, D. G., & Kopetz, S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9681-1 · Cited by 94
Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer
Riva, F., Dronov, O. I., Khomenko, D. I., Huguet, F., Louvet, C., Mariani, P., Stern, M., Lantz, O. J., Proudhon, C., Pierga, J., et al. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.01.006 · Cited by 97
Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer
Liu, X., Liu, L., Ji, Y., Li, C., Wei, T., Yang, X., Zhang, Y., Cai, X., Yang, T., Gao, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.010 · Cited by 86
Ma, F., Guan, Y., Yi, Z., Chang, L., Li, Q., Chen, S., Zhu, W., Guan, X., Li, C., Qian, H., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32536 · Cited by 88
Lee, J., Park, S. S., Lee, Y. K., Norton, J. A., & Jeffrey, S. S. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12537 · Cited by 88
Ikeda, S., Tsigelny, I. F., Skjevik, Å. A., Kono, Y., Mendler, M. H., Kuo, A., Sicklick, J. K., Heestand, G. M., Banks, K. C., Talasaz, A. H., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0479 · Cited by 82
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Macı́as, R. I. R., Cardinale, V., Kendall, T. J., Avila, M. A., Guido, M., Coulouarn, C., Braconi, C., Frampton, A. E., Bridgewater, J. A., Overi, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327099 · Cited by 81
Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.
Zhang, X., Shi, S., Zhang, B., Ni, Q., Yu, X., & Xu, J. (2018) · PubMed Central · Cited by 78
Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Kaseb, A. O., Sánchez, N., Sen, S., Kelley, R. K., Tan, B. R., Bocobo, A. G., Lim, K., Abdel‐Wahab, R., Uemura, M. I., Pestana, R. C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3341 · Cited by 78
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer
Villaflor, V., Won, B., Nagy, R., Banks, K., Lanman, R. B., Talasaz, A., & Salgia, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11801 · Cited by 75
Bhagwat, N., Dulmage, K., Pletcher, C. H., Wang, L., DeMuth, W., Sen, M., Balli, D., Yee, S. S., Sa, S., Tong, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23217-5 · Cited by 75
Shen, N., Zhang, D., Yin, L., Qiu, Y., Liu, J., Yu, W., Fu, X., Zhu, B., Xu, X., Duan, A., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.7177 · Cited by 75
Green, E. A., Li, R., Albiges, L. K., Choueiri, T. K., Freedman, M. L., Pal, S. K., Dyrskjøt, L., & Kamat, A. M. (2021) · European Urology Oncology · doi:10.1016/j.euo.2021.04.005 · Cited by 73
Kim, S. T., Banks, K. C., Lee, S., Kim, K., Park, J. O., Park, S. H., Park, Y. S., Lim, H. Y., Kang, W. K., Lanman, R. B., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00059 · Cited by 72
Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements
Туаева, Н. О., Falzone, L., Porozov, Y. B., Nosyrev, A. E., Трухан, В. М., Kovatsi, L., Spandidos, D. A., Drakoulis, N., Kalogeraki, A. M., Mamoulakis, C., et al. (2019) · Cells · doi:10.3390/cells8101251 · Cited by 70
Ueda, M., Iguchi, T., Masuda, T., Nakahara, Y., Hirata, H., Uchi, R., Niida, A., Momose, K., Sakimura, S., Chiba, K., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11409 · Cited by 73
Pishvaian, M. J., Bender, R. J., Matrisian, L. M., Rahib, L., Hendifar, A. E., Hoos, W. A., Mikhail, S., Chung, V. M., Picozzi, V. J., Heartwell, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13225 · Cited by 70
Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
Grunvald, M. W., Jacobson, R. A., Kuzel, T. M., Pappas, S. G., & Masood, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207651 · Cited by 70
Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2020) · Pancreatology · doi:10.1016/j.pan.2020.12.017 · Cited by 73
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis
Creemers, A., Krausz, S., Strijker, M., van der Wel, M. J., Soer, E. C., Reinten, R. J. A., Besselink, M. G., Wilmink, J. W., van de Vijver, M. J., van Noesel, C. J. M., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.08.002 · Cited by 69
Imamura, T., Komatsu, S., Ichikawa, D., Kawaguchi, T., Miyamae, M., Okajima, W., Ohashi, T., Arita, T., Konishi, H., Shiozaki, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i25.5627 · Cited by 73
Harnessing the Microbiome for Pancreatic Cancer Immunotherapy
Vitiello, G. A., Cohen, D. J., & Miller, G. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.005 · Cited by 65
How to use liquid biopsies to treat patients with cancer
Mattos‐Arruda, L. D., & Siravegna, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100060 · Cited by 70
Recent Discoveries of Diagnostic, Prognostic and Predictive Biomarkers for Pancreatic Cancer
Khomiak, A., Brunner, M., Kordes, M., Lindblad, S., Miksch, R. C., Öhlund, D., & Regel, I. (2020) · Cancers · doi:10.3390/cancers12113234 · Cited by 70
Economopoulou, P., Kotsantis, I., Kyrodimos, E., Lianidou, E. S., & Psyrri, A. K. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.09.012 · Cited by 64
Liquid biopsies for management of pancreatic cancer
Samandari, M., Juliá, M. G., Rice, A. J., Chronopoulos, A., & Hernández, A. E. D. R. (2018) · Translational research · doi:10.1016/j.trsl.2018.07.008 · Cited by 66
Liquid biopsy in pancreatic cancer: the beginning of a new era
Yadav, D. K., Bai, X., Yadav, R. K., Singh, A., Li, G., Ma, T., Chen, W., & Liang, T. (2018) · Oncotarget · doi:10.18632/oncotarget.24809 · Cited by 62
Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma
Ilyas, S. I., Eaton, J. E., Yang, J. D., Chandrasekhara, V., & Gores, G. J. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1655775 · Cited by 60
Bile-Based Cell-Free DNA Analysis Is a Reliable Diagnostic Tool in Pancreatobiliary Cancer
Driescher, C., Fuchs, K., Häberle, L., Goering, W., Frohn, L., Opitz, F. V., Haeussinger, D., Knoefel, W. T., Keitel, V., & Esposito, I. (2020) · Cancers · doi:10.3390/cancers13010039 · Cited by 57
Liquid biopsy in cholangiocarcinoma: Current status and future perspectives
Rompianesi, G., Martino, M. D., Gordon-Weeks, A. N., Montalti, R., & TROISI, R. I. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i5.332 · Cited by 56
Polívka, J., Pešta, M., & Jankú, F. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1110021 · Cited by 57
Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis
Uesato, Y., Sasahira, N., Ozaka, M., Sasaki, T., Takatsuki, M., & Zembutsu, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235623 · Cited by 56
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer
Nordgård, O., Tjensvoll, K., Gilje, B., & Søreide, K. (2018) · British journal of surgery · doi:10.1002/bjs.10782 · Cited by 57
Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients
Christensen, E., Nordentoft, I., Vang, S., Birkenkamp-Demtröder, K., Jensen, J. B., Agerbæk, M., Pedersen, J. S., & Dyrskjøt, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-20282-8 · Cited by 56
Luchini, C., Veronese, N., Nottegar, A., Cappelletti, V., Daidone, M. G., Smith, L., Parris, C. N., Brosens, L. A. A., Caruso, M. G., Liang Cheng, C., et al. (2019) · Cancers · doi:10.3390/cancers11081152 · Cited by 58
The Significance of Liquid Biopsy in Pancreatic Cancer
Qi, Z.-H., Xu, H., Zhang, S.-R., Xu, J.-Z., Li, S., Gao, H.-L., Jin, W., Wang, W.-Q., Wu, C., Ni, Q., et al. (2018) · Journal of Cancer · doi:10.7150/jca.24591 · Cited by 60
High‐throughput isolation of circulating tumor DNA : a comparison of automated platforms
van Dessel, L. F., Vitale, S. R., Helmijr, J., Wilting, S. M., van der Vlugt‐Daane, M., Hoop, E. O., Sleijfer, S., Martens, J. W. M., Jansen, M. P. H. M., & Lolkema, M. P. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12415 · Cited by 58
Circulating tumor DNA analysis in the era of precision oncology
Said, R., Guibert, N. M., Oxnard, G. R., & Tsimberidou, A. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27418 · Cited by 53
Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA
Hur, J. Y., & Lee, K. Y. (2021) · Cancers · doi:10.3390/cancers13153827 · Cited by 51
Reese, K.-L., Pantel, K., & Smit, D. J. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03166-w · Cited by 56
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer
Takai, E., & Yachida, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i38.8480 · Cited by 53
Pritchett, M. A., Camidge, D. R., Patel, M., Khatri, J., Boniol, S., Friedman, E. K., Khomani, A., Dalia, S. M., Baker-Neblett, K. L., Plagnol, V., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00299 · Cited by 50
Next-Generation Biomarkers for Cholangiocarcinoma
Rodrigues, P. M., Vogel, A., Arrese, M. A., Balderramo, D. C., Valle, J. W., & Bañales, J. M. (2021) · Cancers · doi:10.3390/cancers13133222 · Cited by 51
Lapin, M., Edland, K. H., Tjensvoll, K., Oltedal, S., Austdal, M., Garresori, H., Rozenholc, Y., Gilje, B., & Nordgård, O. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3526 · Cited by 49
The Role of Cell-Free DNA in Cancer Treatment Decision Making
Telekes, A., & Horváth, A. (2022) · Cancers · doi:10.3390/cancers14246115 · Cited by 50
Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer
Berger, A. W., Schwerdel, D., Ettrich, T. J., Hann, A., Schmidt, S. A., Kleger, A., Marienfeld, R. B., & Seufferlein, T. T. W. (2017) · Oncotarget · doi:10.18632/oncotarget.23330 · Cited by 48
Invited review—next-generation sequencing: a modern tool in cytopathology
Roy‐Chowdhuri, S., Pisapia, P., Salto‐Tellez, M., Savic, S., Nacchio, M., de Biase, D., Tallini, G., Troncone, G., & Schmitt, F. C. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02559-z · Cited by 47
Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer
Raufi, A. G., May, M. S., Hadfield, M. J., Seyhan, A. A., & El‐Deiry, W. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044238 · Cited by 47
Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?
Krantz, B. A., & O'Reilly, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3169 · Cited by 43
Dreyer, S. B., Jamieson, N. B., Evers, L., Duthie, F. R., Cooke, S., Marshall, J., Beraldi, D., Knight, S. R., Upstill‐Goddard, R., Dickson, E. J., et al. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.04.06 · Cited by 43
Johnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Overview of Molecular Testing of Cytology Specimens
Huang, M., & Wei, S. (2019) · Acta Cytologica · doi:10.1159/000497187 · Cited by 42
Assessment of circulating copy number variant detection for cancer screening
Molparia, B., Nichani, E., & Torkamani, A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180647 · Cited by 43
Tang, H., Partyka, K. A., Hsueh, P. Y., Sinha, J. Y., Kletter, D., Zeh, H. J., Huang, Y., Brand, R. E., & Haab, B. B. (2015) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2015.12.003 · Cited by 41
Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy
Oellerich, M., Schütz, E., Beck, J., & Walson, P. D. (2018) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000566 · Cited by 39
Wilson, H. L., D'Agostino, R. B., Meegalla, N. T., Petro, R. M., Commander, S., Topaloĝlu, Ü., Zhang, W., & Porosnicu, M. (2020) · The Oncologist · doi:10.1002/onco.13573 · Cited by 40
Manne, A., Woods, E., Tsung, A., & Mittra, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.768009 · Cited by 39
Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma
Zhou, J., Huang, A., & Yang, X. (2016) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9801-0 · Cited by 42
Diagnostic and prognostic impact of cell-free DNA in human cancers: Systematic review
Červená, K., Vodička, P., & Vymetalkova, V. P. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2019.05.002 · Cited by 42
Lapin, M., Huang, H. J., Chagani, S., Javle, M. M., Shroff, R. T., Pant, S., Gouda, M. A., Raina, A., Madwani, K., Holley, V. R., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00197 · Cited by 38
Metadata
- Authors
- Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., Van Loon, K., Ko, A. H., Tempero, M. A., Bivona, T. G., Munster, P. N., Talasaz, A., & Collisson, E. A.
- Affiliations
- University of California, San Francisco (US)
- Guardant (United States) (US)
- University of South Alabama (US)
- Cedars-Sinai Medical Center (US)
- 2Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
- Corresponding author
- Collisson, Eric A.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2015-09-30
- Volume
- 5
- Issue
- 10
- Pages
- 1040-1048
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4592417
- OpenAlex
- W2113754052
- Cited by
- 282
- References
- 31
- Citations by year
- 2026: 11 · 2025: 20 · 2024: 16 · 2023: 29 · 2022: 21 · 2021: 31 · 2020: 29 · 2019: 30 · 2018: 35 · 2017: 31 · 2016: 21 · 2015: 8
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (DP2CA174497, K08CA175153)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- cell-free DNA sequencing, circulating tumor DNA, pancreatic cancer, biliary tract cancer, precision oncology, tumor mutation detection, diagnostic accuracy, tumor markers, liquid biopsy
- MeSH terms
- Bile Duct Neoplasms, Carcinoma, DNA, Neoplasm, Humans, Mutation, Neoplasm Staging, Pancreatic Neoplasms, Prognosis, Sensitivity and Specificity, Biomarkers, Tumor, Reproducibility of Results, Disease Progression, Gene Expression Profiling, High-Throughput Nucleotide Sequencing, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
